Ticagrelor or Clopidogrel to reduce ischemic events after Percutaneous Coronary Intervention in chronic coronary syndrome in clopidogrel naive patient: the ALPHEUS Naive sub-study.

26 August 2023 (10:15 - 10:24)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Johanne Silvain

Sorbonne University, Paris (France)

4 More presentations in this session

Presentation thumbnail

Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: A systematic review and meta-analysis

Miss R. Markides (Cambridge, GB)

Abstract Slides Video

Presentation thumbnail

Clopidogrel vs. aspirin in the chronic maintenance period following percutaneous coronary intervention in high thrombotic and high bleeding risk patients:sub-analysis of the HOST-EXAM Extended study

Doctor J. Chung (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

Ticagrelor versus clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome: a post-hoc analysis of the ALPHEUS study

Professor B. Lattuca (Nimes, FR)

Abstract Slides Video

Presentation thumbnail

Meta-analysis of 3-month vs 12-month dual anti-platelet therapy after percutaneous coronary intervention

Doctor F. Gerardo (Amadora, PT)

Abstract Slides Video

Access the full session

Session thumbnail

Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease

The Event

Event poster

ESC Congress 2023

26 August 2023 10:15 CET

You may be interested in

Congress Presentation

P2Y12 inhibitor loading time before elective PCI and the prevention of myocardial necrosis

Congress Session

Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease

Congress Session

Late-Breaking Clinical Trials: antithrombotic strategies and PCI advances

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources